Penumbra just dropped its Q3 2026 scorecard and the stock barely flinched, easing about 1% to roughly US$319 after the release. That muted move hides a sharper story. The medical device specialist posted about US$410.1 million in quarterly revenue and roughly US$42.3 million in underlying profit, while the trailing P/E multiple sits near 80x. Traders cooled the share price, yet the real tension sits in that gap between premium valuation and the earnings power on display. The market is pricing perfection. The latest numbers show how much pressure that expectation now carries.
Love Penumbra's revenue scale and profitability but uneasy about paying an 80x P/E for it? Take a look at our screener of quality stocks with stronger balance sheets and more grounded valuations through the list of solid balance sheet and fundamentals stocks (25 results)
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): US$410.1 million vs. US$354.7 million (higher year on year)
- Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): US$42.3 million vs. US$45.9 million (lower year on year)
- Basic EPS (Q3 2026 vs Q3 2025): US$1.07 vs. US$1.17 (declined year on year)
- Trailing 12 Month Revenue (Q3 2026 TTM vs Q3 2025 TTM): US$1.56b vs. US$1.33b (higher over the last year)
Earnings for Penumbra look solid on paper, but cash flows tell you how much real money is dropping into the business and what investors might actually be paying for that stream. If you focus on Penumbra's cash generation rather than the income statement headlines, the stock could be a slight 13% overvalued.
Penumbra Milestones Back The Growth Playbook
Penumbra bulls argue that execution across thrombectomy, embolization and manufacturing can carry the story well beyond stroke alone.
"The main factor that has to go right is that Penumbra maintains strong execution across thrombectomy, embolization and manufacturing expansion, while integrating smoothly into Boston Scientific following the planned acquisition closing in 2026."
On thrombectomy, FDA clearance for Lightning CAVT in DVT plus strong BOLT DVT and PE data show real clinical traction. This is echoed in Q3 VTE revenue growth of 26% and neuro growth of 19.3%. Manufacturing is still in investment mode, with Costa Rica not yet online, and acquisition related costs plus the withdrawn 2026 guidance indicate that the Boston Scientific leg of the thesis is progressing but not yet de risked.
One Narrative disagrees with today's price. → See where this Narrative says Penumbra should trade.
Penumbra Bear Case: Margin Friction And Deal Fog
Bearish investors worry that Penumbra’s wider product slate and heavier spend create more ways for things to go wrong.
"While Penumbra is advancing multiple thrombectomy and embolization platforms, including THUNDERBOLT, Lightning CAVT for DVT and expanded stroke studies, this wider product footprint increases exposure to regulatory reviews, device performance questions and post clearance safety actions such as the Class II RED 62 catheter recall."
The Class II RED 62 recall is real, yet Q3 thrombectomy driven revenue still reached US$410.1 million with VTE and neuro both growing double digits. The sharper stress point this quarter is margin execution. Net income and EPS declined year on year and acquisition costs plus pulled 2026 guidance leave operating leverage and Boston Scientific timing questions unresolved.
Hunt For Mispriced Earnings Power
Penumbra just showed how a premium multiple can sit awkwardly beside lumpier profit trends. The real opportunity is finding stocks that could be undervalued before the market corrects them.
- Company 1 - 46% below our estimate - expands from trackers into storage and inverters so higher margin add-ons cushion project delays and grid bottlenecks.
- Company 2 - 41% below our estimate - grows a rental matting platform that turns long utility and pipeline work into steadier recurring site access fees.
- Company 3 - 48% below our estimate - moves from basic assembly to co-designing complex hardware so design input locks in deeper manufacturing relationships.
Those are three of them. See every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com